Traders should monitor upcoming clinical trial milestones and data readouts, as success could validate IDE849's potential and lead to future partnerships or accelerated development. However, no immediate revenue or financial impact is expected.
Price Chart
Executive Summary
IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigational drug IDE849 in combination with AstraZeneca's Imfinzi for treating extensive-stage small cell lung cancer. The study will be globally sponsored by IDEAYA, with AstraZeneca supplying the drug.
Key Facts
- IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026.
- The collaboration will evaluate IDE849 (a DLL3 TOP1 antibody-drug conjugate) in combination with Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC).
- IDEAYA will sponsor the global Phase 1 clinical trial, while AstraZeneca will supply Imfinzi.
- The trial is part of a broader multi-site global Phase 1 study in DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.
Financial Impact
Undisclosed financial terms; IDEAYA will sponsor the study, and AstraZeneca will supply Imfinzi.
Risk Factors
- Clinical trial may not meet efficacy or safety endpoints.
- Regulatory delays or trial enrollment challenges could slow development.
- Dependence on third-party collaborator (AstraZeneca) for supply and trial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-148777 |
| Document: 0001193125-26-148777-index-headers.html | 0001193125-26-148777 |
| Document: 0001193125-26-148777-index.html | 0001193125-26-148777 |
| Document: 0001193125-26-148777.txt | 0001193125-26-148777 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.05 (+2.60%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.05 (+2.12%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.05 (−28.47%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.05 (−34.24%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.05 (−31.99%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.05 (+30.46%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.05 (+12.89%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.05 (+19.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access